US 12,030,885 B2
Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors
Andrew W. Buesking, Wilmington, DE (US); Richard B. Sparks, Wilmington, DE (US); Andrew P. Combs, Kennett Square, PA (US); Brent Douty, Fallowfield, PA (US); Nikoo Falahatpisheh, Wilmington, DE (US); Lixin Shao, Wilmington, DE (US); Stacey Shepard, Wilmington, DE (US); Eddy W. Yue, Landenberg, PA (US); Artem Shvartsbart, Kennett Square, PA (US); David M. Burns, Plymouth Meeting, PA (US); and Daniel Levy, Philadelphia, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Feb. 23, 2021, as Appl. No. 17/183,253.
Application 16/165,390 is a division of application No. 15/631,417, filed on Jun. 23, 2017, granted, now 10,138,248, issued on Nov. 27, 2018.
Application 17/183,253 is a continuation of application No. 16/591,017, filed on Oct. 2, 2019, granted, now 10,975,088.
Application 16/591,017 is a continuation of application No. 16/165,390, filed on Oct. 19, 2018, granted, now 10,479,795, issued on Nov. 19, 2019.
Claims priority of provisional application 62/354,509, filed on Jun. 24, 2016.
Prior Publication US 2022/0251087 A1, Aug. 11, 2022
Int. Cl. A61K 31/53 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 487/04 (2013.01) [C07D 471/04 (2013.01); C07D 519/00 (2013.01); C07B 2200/13 (2013.01)] 20 Claims
 
1. A compound, which is 3-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-N-(4-cyanobicyclo[2.1.1]hexan-1-yl)-4-(methyl-d3)benzenesulfonamide, or a pharmaceutically acceptable salt thereof.
 
3. The compound of claim 1, which is a crystalline free base of 3-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-N-(4-cyanobicyclo[2.1.1]hexan-1-yl)-4-(methyl-d3)benzenesulfonamide.